The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.
The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.
Drug Review Updates
Olaratumab (Lartruvo) for Advanced Soft Tissue Sarcoma
(Pending Submission as of August 22, 2017)
Alectinib (Alecensaro) for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (second line)
(Open for Input on Submission until September 1, 2017)
Brentuximab (Adectris) for Hodgkin’s Lymphoma (post-ASCT) Resubmission
(Open for Input on Submission until August 24, 2017)
Panitumumab (Vectibix) for Left Sided Metastatic Colorectal Cancer
(Pending Submission as of August 10, 2017)